Butyrate, a four-carbon fatty acid, and its two-carbon metabolic product, acetate, are inducers of y-globin synthesis. To test whether other short-chain fatty acids share this property, we first examined whether propionic acid, a three-carbon fatty acid that is not catabolized to acetate, induces y-globin expression. Sodium propionate increased the frequency of fetal hemoglobin containing erythroblasts and the y / y + mRNA ratios in adult erythroid cell cultures and F reticulocyte production in a nonanemic juvenile baboon. Short-chain fatty acids containing five (pentanoic), six (hexanoic), seven (heptanoic), eight (octanoic), and nine (nonanoic) carbons induced y-globin expression (as measured by increase in y-positive erythroblasts and y / y + 8 mRNA ratios) in adult erythroid burst-forming unit cultures. There HARMACOLOGICAL INDUCTION of fetal hemoglobin (HbF) in humans or in other primates has been achieved with several agents. One category includes cytotoxic drugs that induce HbF by altering the kinetics of erythropoiesis.' Hemopoietins, such as erythropoietin, stimulate HbF production by inducing rapid erythroid regeneration? Induction of HbF production can also be achieved in vitro or in vivo by butyric acid and its analogues.
HARMACOLOGICAL INDUCTION of fetal hemoglobin (HbF) in humans or in other primates has been achieved with several agents. One category includes cytotoxic drugs that induce HbF by altering the kinetics of erythropoiesis.' Hemopoietins, such as erythropoietin, stimulate HbF production by inducing rapid erythroid regeneration? Induction of HbF production can also be achieved in vitro or in vivo by butyric acid and its analogues.
Butyrate, a well-known inducer of terminal differentiation of erythroleukemia cells,3 was initially found to induce embryonic globin expression when administered to anemic chicken in combination with 5-azacytidine: Subsequently, it was shown that butyrate inhibits the fetal-to-adult globin gene switch in sheep,' induces fetal globin production in cultures of erythroid progenitors from normal adults and persons with sickle cell disease: and stimulates HbF production in adult baboon^.^,^ Induction of HbF synthesis has also been observed in patients with P-thalassemia or sickle cell disease.' Because acetate, a product of butyric acid metabolism, also induces HbF in erythroid cultures or after administration to baboons," we asked whether y-gene inducibility is a general characteristic of short-chain fatty acids, rather than a property limited to butyrate and its analogues.
In this report, we show that short-chain fatty acids with up to nine carbons induce HbF synthesis in cultures of human erythroid progenitors, suggesting that a common mechanism underlies the induction of y-gene expression by these compounds. Our results raise the possibility that clinically used short-chain fatty acid derivatives may share the property of HbF inducibility and may be relevant to the treatment of the &chain hemoglobinopathies. Such HbF inducers can be discovered by screening patients for the presence of elevated F cells. Pittsburgh, PA), 0.2 U/mL recombinant human erythropoietin (Genetics Institute, Cambridge, MA), 30% charcoal-treated fetal calf serum (HyClone), 0.1 mmoVL 2-mercaptoethanol (Sigma, St Louis, MO), and varying concentrations of the compound being tested. All fatty acids used in this study were purchased from Sigma. Cultures were maintained in a high humidity, 37"C, 5% COz incubator. After 14 days of culture, hemoglobinized colonies, derived from burstforming units-erythroid (BFUe), were identified using a dissecting microscope, plucked, washed, and subjected to analysis.
Measurement of HbF-containing cells by immunojuoresence. For measurement of F-positive erythroblasts, BFUe colonies were washed, dispersed, fixed in methanol, and labeled with a mouse anti-y-chain monoclonal antibody followed by a goat antimouse F(ab'),-fluorescein isothiocynate antibody, as previously described." The percentage of y-positive cells was determined using a Zeiss (Thornwood, NY) universal fluorescent microscope. Staining was also performed using an anti-&chain antibody to confirm that essentially all erythroblasts contained globin. Measurements of F cells, F reticulocytes, and HbF were performed using previously described method^.^^'^^^'^^'' For F-cell measurements, duplicate counts of at least 1 , OOO erythrocytes were performed. F reticulocytes
were measured with counts of at least 1.000 reticulocytes. mRNA analysis. Total RNA was prepared from BFUe colonies as described." Globin mRNA was analyzed by RNAse protection using human y and p pro he^,'^,'^ yielding protected fragment sizes of 170 and 205 bp, respectively. y-and @-globin mRNA was quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Primate studies. The sodium salt of propionic acid (Sigma) was dissolved in water and neutralized with I N HCI to a pH of 7.2 to 7.4. Pentanoic acid (Sigma) was neutralized with a 50% sodium hydroxide solution. Solutions were filter-sterilized, diluted in 500-to 1,000-mL bags of sterile water, and administered as continuous intravenous infusions in healthy juvenile baboons (Pupio cynocephuh ) . The protocols used were approved by the Animal Care Committee of the University of Washington (Seattle, WA). All animals received iron dextran, (100 mg), vitamin B12 (100 mg), and folic acid (5 mg) intramuscularly, weekly. The proportion of reticulocytes containing HbF (F reticulocytes) was evaluated using a previously described method." The animals were monitored by a veterinarian, and no undesirable effects were observed. Detailed toxicologic studies were not performed because they were beyond the scope of this report. Human studies. Blood was obtained from normal volunteers and from valproic acid-treated inpatients at the Yakima Valley School of the Department of Social and Health Services (Selah, WA) and outpatients at the seizure clinic of the Harborview Medical Center (Seattle, WA). All human studies have been reviewed and approved by the Human Subjects Committee of the University of Washington and the relevant committee of the Yakima Valley School.
RESULTS
Propionic acid induces y-globin expression in culture and in vivo. In view of our results showing induction of yglobin expression by sodium acetate," we examined whether the three-carbon fatty acid, propionic acid which is not catabolized to acetic acid,"*'* induces y-globin expression in erythroid cultures. Mononuclear cells were isolated from the peripheral blood of adult individuals and cultured in the presence of charcoal-absorbed fetal calf serum. This medium was used because previous studies have shown that charcoal absorption removes from the FCS factors that induce yglobin expression." To this media, sodium propionate in concentrations ranging from 0 to 2 mmoVL was added. After 14 culture days, well-hemoglobinized, mature erythroid colonies were collected from the plates; they were pooled and were used for measurement of the frequency of y-positive erythroblasts after staining with anti-y-chain fluorescinated monoclonal antibodies or for RNA preparation and measurement of the y / y + p mRNA ratios by RNAse protection. F reticulocytes increased from the pretreatment baseline value of 2.1% to a peak of 29.2% on day 12 of treatment. The degree of induction of F reticulocytes was higher than that previously observed in baboons treated with continuous infusion of 2 g k g sodium butyrate.'.' After the initial induction, the level of F reticulocytes decreased to about lo%, although the animal was being continuously infused with sodium propionate. A similar decrease of F-reticulocyte production during treatment has been observed before in the animals treated with sodium acetate." It is unclear whether this decrease in y-globin expression is due to tachyphylaxis." F cells increased from a pretreatment baseline value of 6.3% to a peak value of 16%. The chemically measured HbF increased from 1.1% to 2.7%. The degree of elevation of F cells and of the chemically measured HbF was similar to that previously observed in animals treated with continuous infusion of 2 @g sodium butyrate."
In parallel to the induction of F reticulocytes, there was an increase in the count of reticulocytes from 0.7% on treatment day 2 to 3.8% on day 9. It was not clear whether this reticulocytosis was elicited by propionate or whether it was the result of a decrease in hematocrit from 35% to 31.5% because of withdrawal of 50 mL of blood on day 4.
To answer this question, the animal was again treated for 10 days, starting on day 42, by infusion of the same amount of sodium propionate. During this treatment, the hematocrit remained stable at 35% to 36%, and there was no increase of reticulocytes. However, F reticulocytes increased form a baseline level of 4.5% on day 41 to 30% by day 51 (Fig 2) .
These results showed that the induction of y-globin expression by sodium propionate was due to an effect of this compound on y-globin synthesis rather than to an indirect effect elicited by induction of erythroid regeneration.
Pentanoic acid induces y-globin expression in human BFUe cultures. The five-carbon fatty acid, pentanoic acid, was next evaluated with similar methodology. Mononuclear cells from three normal individuals and two patients with sickle cell disease were used for erythroid cultures (Fig 3) . In the five control cultures performed without sodium pentanoate, 14. mmol/L. Therefore, sodium pentanoate increased y mRNA up to sixfold over the baseline value. In the third experiment, the y/y + ratio increased fivefold (from a baseline value of 0.04 to a value of 0.195 at 0.5 mmoVL sodium pentanoate). Therefore, this compound induced y-globin expression at concentrations that were about fourfold to fivefold lower than those used in cultures performed with sodium propionate.
Sodium pentanoate was subsequently administered as a continuous infusion at 4gkgld to a juvenile baboon for 10 days (Fig 4) . F reticulocytes increased from 1.8% on day 3 to 12.6% on day 12. There was an unexplained decrease of hematocrit from 35% on day 5 to 28% on day 9. However, reticulocytes did not increase except on day 10. Because the increase in F reticulocytes preceded the appearance of reticulocytosis, it is unlikely that it was the result of the induction of erythroid regeneration; but, rather, it represented induction of y expression by sodium pentanoate. The level of increase in F reticulocytosis (from 1.8% to 12.6%) in this animal was lower than that observed in the animal treated with sodium propionate (Fig 2) . The animal of Fig 4 was also treated with 4 g k g sodium propionate, and F reticulocytes increased from 2.2% to 13.5%, suggesting that the lower F- reticulocyte response (compared with that of the animal of Fig 2) reflected differences between animals rather than differences between compounds.
L determination, the mean of the yIy + p ratio at 0.5 mmol/ L is 0.175. Thus, on the average, the y-positive erythroblasts increased by 2.9-fold, whereas the y / y + ratios increased
We subsequently administered valproic acid in escalating doses in a baboon (week 1, 15 mg/kg/d; week 2, 30 mg/kgI d; week 3, 60 mg/kg/d; week 4, 75 mg/kg/d). The serum levels of valproic acid on week 4 were l20 pgImL, ie, at the therapeutic range for humans. However, there was no increase in F reticulocytes in this animal, and the treatment was discontinued. One of us (G.D.) examined whether valproic acid increases HbF in patients receiving this compound for treatment of epilepsy. About 30% of valproic acid-treated patients had elevated F cells.22 A more extensive study was undertaken to substantiate this effect. Eighty individuals treated with valproic acid as outpatients in a University of Washington clinic were examined with measurements of F cells. Almost one third of these patients had higher F-cell levels than that of controls (Fig 6B) . In a subsequent study, 21 individuals undergoing chronic valproic acid treatment as inpatients were examined. Seven of these patients had F-cell levels higher than the upper limit of normal controls (Fig 6C) . One patient showed a striking phenotype consisting of 58% F cells and 15% HbF as measured by alkali denaturation. This female patient had levels of hemoglobin and hematocrit within normal range, but she had elevated MCV and MCH and hemoglobins A and F on hemoglobin electrophoresis. Both parents of this patient were hematologically normal. The father had a normal number of F-cells, while the mother had 11% F-cells indicating that she was a carrier of the heterocellular variant of hereditary persistence of fetal hemoglobin (HPFH). We postulate that our patient is a carrier for heterocellular HPFH; the high level of HbF and F-cells suggest that valproic acid may be an effective inducer of fetal hemoglobin in patients carrying heterocellular HPFW or in anemic patients carrying transcriptionally active y globin genes.
Six-to nine-carbon fatq acids induce y-globin expression in human BFUe cultures. The induction of y-globin by six-, seven-, eight-, and nine-carbon fatty acids was subsequently tested in cultures of erythroid progenitors from adult individuals. As shown in Fig 7, hexanoic acid Fig  7B) .
In one experiment with heptanoic acid, the frequency of y-globin-positive erythroblasts increased from 12.9% ?
3.5% at 2 mmollL to 30.6% 2 2.6% at 4.0 mmom and the yIy + p mRNA ratio from 0.045 to 0.1 12. In a second experiment, only yIy + p ratios were measured and increased from a baseline value of 0.027 to a peak level of 0.34 at 5 mmollL sodium heptanoate.
The effect of eight-carbon fatty acid, octanoic acid was tested in cultures of BFUe from four normal adults at concentrations ranging from 0 to 2.5 mmoVL (Fig 8) . not show the dose-response relationship observed with the other short-chain fatty acids. Of the two cultures used for RNA studies, one responded with an increase in the yIy + p mRNA ratio; the other did not. It is possible that the decreased solubility of this fatty acid was responsible for the inconsistent results.
DISCUSSION
Butyrate and its analogues have been known to induce HbF in erythroid cultures and in animal but only recently has evidence of HbF induction in patients with sickle cell disease or with ,&thalassemia been obtained.'" Pemne et a19 have shown that patients with homozygous @-thalassemia receiving intravenous infusions of arginine butyrate respond with substantial increases in y-globin production.' A butyrate analogue, 4-phenylbutyric acid, has been used in the treatment of patients with urea cycle disordersz4; several of these patients have elevated F cells,23 thus suggesting that phenylbutyrate, similar to butyrate, induces HbF in vivo. Induction of F-cell production by phenylbutyrate has also been shown in a proportion of patients with sickle cell disease or &thalassemia intermedia." Arginine butyrate and phenylbutyrate have disadvantages related to the mode of administration. Arginine butyrate requires administration by continuous intravenous infusion,' whereas phenylbutyrate, although administered orally, requires consumption of up to 40 tablets per day by the adult patients." Such limitations, as well as the possibility of discovering compounds that are more potent than butyrate and its analogues, justify the search for new inducers of HbF production.
Butyrate is rapidly catabolized to acetate.".25 Sodium acetate induces HbF in BFUe cultures'" and in nonanemic baboons,'" suggesting that either the catabolism to acetate is the cause of induction of y-gene expression by butyrate or that y-globin gene expression can be independently induced by both two-(acetate) and four-(butyrate) carbon fatty acids. The latter possibility is supported by our finding that propionic acid, a three-carbon fatty acid that is not catabolized to acetate,I7.'* induces y-globin expression in BFUe cultures and in the adult nonanemic baboon. The finding that fatty acids with five to nine carbons are HbF inducers strongly suggests that induction of y-globin expression is a common property of all short-chain fatty acids; perhaps, all these compounds induce y-globin expression by a common mechanism. The degree of induction of y globin appears to correlate with the number of carbons contained in the fatty acid: three-, four-, and five-carbon fatty acids are more potent inducers of y-globin expression as compared with fatty acids containing six to nine carbons (Fig 9) .
In addition to its effect on HbF induction, butyrate has several pleiotropic effects on various cellular systems. Typically, butyrate induces the appearance of differentiated cellular phenotypes,"B26*z7 but the opposite (ie, inhibition of differentiation) has also been observed.** DNA segments containing butyrate response elements have been identified in the human immunodeficiency virus long terminal repeatz9 and in the promoter region of various gene^.^'.^' Specific butyrate response motifs have not yet been detected in the promoters of fetal and embryonic globin genes, although regions in which likely butyrate-responsive elements are located have been It has been proposed that butyrate effects gene expression indirectly, by modulating the acetylation of histones. 35 Butyrate is an inhibitor of histone dea~etylase,~~ and, perhaps, the inhibition of this enzyme and the accompanying changes in ~h r o m a t i n~~"~ underlie the induction of HbF. It is of interest that the short-chain fatty acids we used in our experiments have been shown to inhibit histone dea~etylase.'~.~~ Whether histone hyperacetylation is involved in the induction of y-globin gene expression by these compounds remains to be determined.
Previous studies have addressed the question of whether short-chain fatty acids other than butyrate induce y-globin expression. Safaya et aP9 used K562 cells transfected with a construct consisting of a *y-gene promoter truncated to
[mM] Fatty Acid Concentration position -381 and linked to the firefly luciferase gene. In other constructions, the above recombinant was linked to short sequences from the core element of DNase-I hypersensitive site-2 of the P-globin locus control region. The transfected K562 cells were cultured in the presence of C3 to C6 fatty acids, and the effects on luciferase activity were measured. The results were interpreted to indicate that the C3 to C6 fatty acids increase y-promoter activity in this transient expression system. However, the experimental system used in the study of Safaya et a1 detects whether a compound acts as general erythroid inducer or as a general globin inducer rather than as a specific inducer of y globin gene expression. That the globin genes contain sequences which respond to erythroid cell inducers has been documented previou~ly.~*~' To test, using transient or stable transfection assays, whether a compound preferentially induces the y-globin genes over its general effect on globin gene induction, cotransfections of y-gene and P-globin-gene constructs need to be used, and the quantitative effects of the inducer on each globin promoter compared. If only ygene constructs are used, specific effects on y-globin expression cannot be differentiated from nonspecific effects on globin gene expression. Similar criticism applies to studies in which K562 cells (or other human erythroleukemia cell lines) are used and the effects of various compounds on expression of endogenous y-globin genes are asses~ed.~' In the case of K562 cells, specificity of y-gene induction can be claimed only if the degree of y-gene induction surpasses the degree of a-globin gene induction, as assessed by a sensitive mRNA quantitative assay such as RNAse protection. The human erythroid cultures used in our studies do not have such limitations because the specificity of induction of endogenous y-globin genes is assessed by the preferential increase of y mRNA over P mRNA, which results in the increased yIy + p mRNA ratios. This increase in y-globin For personal use only. on October 27, 2017. by guest www.bloodjournal.org From mRNA results in increased synthesis of y-globin protein, as indicated by the increased frequencies of erythroblasts stained with the anti-y-globin chain fluorescent antibodies.
Ex vivo assays, such as the erythroid culture assay we have used in this study, cannot always predict the in vivo induction of HbF by a pharmacological agent. Furthermore, the erythroid cultures can be exposed to drug concentrations that may not be attainable in vivo without prohibitive toxic effects. To test for effects in vivo, two nonanemic baboons were treated with propionic or pentanoic acid. These compounds were administered by continuous infusion using protocols we have previously applied in studies of sodium butyrate*.*' a-aminobutyric acid,' or acetate."
Both animals responded with induction of F reticulocytes and increases of F cells. The magnitudes of those responses were similar to those we have observed previously in animals treated with or acetate." These results as well as the recent observation that HbF is elevated in children with propionic acidemia43 indicate that short-chain fatty acids, other than butyrate or acetate, can induce HbF in vivo.
It is unlikely that the specific fatty acids we used in our experiments will be used for therapeutic induction of HbF in humans; induction of HbF was observed when high concentrations of these compounds were administered to baboons by continuous infusion. However, it is possible that other compounds, which are structural derivatives of the fatty acids we used in our experiments, also share the property of HbF inducibility. Such derivatives may prove useful in the treatment of hemoglobin disorders. Our findings with valproic acid provide a paradigm for the discovery of shortchain fatty acid derivatives that are already approved for human use and that possess the property of y-globin gene inducibility.
As we have shown here, valproic acid, a widely used anticonvulsant that is a derivative of pentanoic acid, induced y-globin expression in human erythroid cell cultures. In addition, screening of patients treated with this drug showed that valproic acid induces HbF production in vivo. The risk of hepatotoxicity may limit the use of this compound as an inducer of HbF in patients with @-chain hemoglobinopathies. However, several other compounds that are structural derivatives of short-chain fatty acids are already approved for human use, and, among these compounds, drugs that are HbF inducers may exist. Measurements of F cells in patients receiving such drugs will identify new inducers of HbF. The induction of HbF by such compounds is expected to be potentiated in patients with sickle cell disease or homozygous P-thalassemia in whom y-gene transcription already occurs in a portion of the patient's erythropoiesis.
